Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/bjd/ljaf039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol.
Skin Health Dis
June 2025
Unit for Paediatric and Population-Based Dermatology Research, St John's Institute of Dermatology, King's College London, London, UK.
Background: Atopic dermatitis (AD) is a common chronic inflammatory skin condition. Currently, there is a lack of real-world evidence regarding the effectiveness of systemic therapies for moderate-to-severe AD. Abrocitinib is a novel Janus kinase 1 selective inhibitor licensed for AD in adults and adolescents requiring systemic treatment.
View Article and Find Full Text PDFExposure-response of ciclosporin and methotrexate in children and young people with severe atopic dermatitis: a secondary analysis of the TREatment of severe Atopic dermatitis Trial (TREAT).
Clin Exp Dermatol
July 2025
Department of Paediatric Dermatology, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, UK.
This is a secondary analysis of a multicentre randomized controlled trial of ciclosporin and methotrexate in children and young people (CYP) with severe atopic dermatitis (AD). Longitudinal trough ciclosporin and erythrocyte methotrexate polyglutamate (MTX-PG) concentrations were measured to evaluate their associations with treatment response and adverse events. Both ciclosporin (4 mg kg-1 daily) and methotrexate (0.
View Article and Find Full Text PDFMethotrexate and ciclosporin improve skin biomarkers in paediatric atopic dermatitis: results from the TREatment of severe Atopic eczema Trial.
Br J Dermatol
July 2025
St John's Institute of Dermatology, Guy's Hospital, London, UK.
Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis.
Allergy
August 2025
Pfizer Corporation Austria GmbH, Vienna, Austria.
Background: Abrocitinib has demonstrated long-term efficacy (48 weeks) and safety (~4 years) in adults and adolescents with moderate-to-severe atopic dermatitis (AD). This analysis evaluated abrocitinib efficacy in adolescents through 112 weeks, and safety of up to 4.6 years of exposure.
View Article and Find Full Text PDFThe UK-Irish Atopic eczema Systemic TherApy Register (A-STAR): baseline characteristics of the cohort.
Br J Dermatol
April 2025
Unit for Population-based and Paediatric Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, UK.